Skip to main content
Contact Us
Subscribe
E-Edition
76°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
enGene Holdings Inc. - Common Stock
(NQ:
ENGN
)
4.550
+0.110 (+2.48%)
Streaming Delayed Price
Updated: 10:52 AM EDT, Apr 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about enGene Holdings Inc. - Common Stock
< Previous
1
2
Next >
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
April 01, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
March 10, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in the Leerink Partners Global Healthcare Conference
March 04, 2025
From
enGene Holdings Inc.
Via
Business Wire
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
February 18, 2025
Via
Benzinga
Why Are EnGene Holdings Shares Trading Lower Friday?
June 14, 2024
EnGene Holdings Inc. shares are trading lower Friday after the company, reported its financial results for the second quarter.
Via
Benzinga
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 31, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
January 30, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 30, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
December 19, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in Upcoming Investor Conferences
November 25, 2024
From
enGene Holdings Inc.
Via
Business Wire
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
November 18, 2024
Via
Benzinga
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024
From
enGene Holdings Inc.
Via
Business Wire
Why enGene Holdings Stock Is Trading Higher
October 25, 2024
enGene shares are trading higher by 6.7% during Friday's session. The company announced it generated approximately $60 million in proceeds from a private placement.
Via
Benzinga
enGene Announces $60 Million Private Placement Financing
October 25, 2024
From
enGene Holdings Inc.
Via
Business Wire
IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
October 24, 2024
Via
Benzinga
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 22, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
October 21, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 01, 2024
From
enGene Holdings Inc.
Via
Business Wire
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
September 26, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
September 10, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in Upcoming Investor Conferences
August 28, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 24, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
July 24, 2024
From
enGene Holdings Inc.
Via
Business Wire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024
June 14, 2024
ENGN stock results show that enGene Holdings missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
June 14, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
enGene Holdings Inc.
Via
Business Wire
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
May 15, 2024
From
enGene Holdings Inc.
Via
Business Wire
Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
February 15, 2024
Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial
Via
Benzinga
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.